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Th17 cells play an important physiological role at mucosal barriers, and are involved in inﬂammatory
responses to pathogens. Th17 cells and their signature cytokine IL-17 are also present in salivary gland
lesions of primary Sj€ogren's syndrome (pSS) patients and can be elevated in their peripheral blood. In pSS
patients, clear correlations between increased Th17 cell activity and symptoms of the disease have not
been found, but Th17 cells may contribute to disease progression, for example by supporting autoreactive
B cell responses. In mouse models of pSS, Th17 cells play an important role in pathogenesis, particularly
at disease onset, when there is a disturbed balance between T effector and T regulatory cells. Studying the
pathogenicity of Th17 cells in humans is complicated due to the plasticity of this cell subset, allowing
them to obtain different effector functions depending on the local environment. Th17 cells can develop
towards Th17.1 cells, producing both IL-17 and IFN-g, or even towards Th1-like cells producing IFN-g in
the absence of IL-17. These effector subsets may be more pathogenic than bona ﬁde Th17 cells. Co-
expression of IFN-g by Th17 cells has been shown to promote chronic inﬂammation in several auto-
immune diseases and may also contribute to pSS pathogenesis. In line with the noticeable role of IL-17 in
pSS mouse models, interference with Th17 cell generation, recruitment or effector functions (e.g. IL-17
inhibition) can prevent or ameliorate disease in these models. Therapies targeting Th17 cells or IL-17
have not been tested so far in pSS patients, although treatment with rituximab seems to lower local
and systemic IL-17 protein levels, and to a lesser extent also chemokine receptor-deﬁned Th17 cells. In
this review we discuss current knowledge of pathogenicity and plasticity of Th17 cells in human pSS and
murine models of pSS. We postulate that plasticity towards Th17.1 cells in pSS may enhance pathoge-
nicity of Th17 cells at the main target sites of the disease, i.e. salivary and lacrimal glands.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Primary Sj€ogren's syndrome (pSS) is a systemic autoimmune
disease, primarily affecting the salivary and lacrimal glands. Oral
and ocular dryness, fatigue and pain are predominant symptoms of
pSS. The disease is clinically heterogeneous and many extra-
glandular organs can be involved during the course of the disease
[1]. The pathophysiology of pSS is multi-facetted and not
completely understood. Both environmental and genetic factors are
likely involved in disease initiation, and the few gene poly-
morphisms that are associated with pSS are related to components
of both innate and adaptive immune systems [2]. No poly-
morphisms in genes encoding salivary or lacrimal components
have been identiﬁed. Involvement of the adaptive immune system
is evident in the affected exocrine glands of pSS patients, where
main histopathological ﬁndings include periductal focal inﬁltration
of mononuclear cells, largely consisting of CD4þ T cells and B cells
[3]. These periductal inﬁltrates can be organized into ectopic
lymphoid structures with segregated T and B cell areas. In
approximately 25% of the patients, these structures contain
germinal centers, which promote local expansion of (auto)antigen-
speciﬁc (memory) B cells [4,5]. The occurrence of ectopic germinal
centers, together with hypergammaglobulinemia and presence of
autoantibodies underlines the important role of B cell hyperactivity
in pSS pathogenesis [6]. It is, however, important to note that CD4þ
T cells predominate the periductal inﬁltrates in patients with mild
lesions [3]. Growing evidence suggests that the crosstalk between
CD4þ Tcells and B cells forms a crucial step in pSS pathogenesis and
a suitable target for treatment [7,8].
Different CD4þ T cell subsets seem to contribute to pSS patho-
genesis, including T helper 1 (Th1) cells, follicular T helper (Tfh)
cells and T helper 17 (Th17) cells, although the relative importance
of each subset remains a matter of debate. After the ﬁrst discoveries
of a link between Th17 cells and autoimmunity, several human and
murine studies investigated the role of Th17 cells in pSS patho-
genesis, as summarized in Table 1. In 2008, the ﬁrst studies showed
that IL-17, the signature cytokine of Th17 cells, is present within
lymphocytic inﬁltrates of minor salivary gland tissue from pSS
patients [9,10]. Presence of IL-17 was predominantly observed in
CD4þ T cell-rich areas of the periductal inﬁltrates [10]. Also IL-17
mRNA levels were elevated in minor salivary glands of pSS pa-
tients, compared with non-SS sicca patients [11]. Subsequent
studies focused on the presence of Th17 cells within the glands.
However, there is not a single marker that identiﬁes Th17 cells
exclusively. In current literature, Th17 cells have been identiﬁed
either by expression proﬁles of their signature cytokines IL-17 and
IL-22, by the expression of chemokine receptors (CCR6, CCR4,
CD161, podoplanin) and/or bymeans of transcription factors (RORg,
STAT3). To complicate matters further, Th17 cells can acquire
functional characteristics of regulatory T (Treg) cells, Th1 cells and
Tfh cells and even can downregulate IL-17 production, illustrating
the plasticity of this cell subset [12].
In this review wewill discuss current knowledge of Th17 cells in
pSS pathogenesis and mouse models of pSS, including their
phenotype, localization, function and correlation with clinical fea-
tures of the disease. We will focus on the relation between path-
ogenicity and plasticity of Th17 cells and postulate that plasticity
towards Th1-like cells in pSS may enhance pathogenicity of
Th17 cells at the main target sites of the disease, i.e. salivary andlacrimal glands.
2. Role of Th17 cells in pSS
Th17 cells play an important physiological role at mucosal sites
of healthy individuals. The main effector cytokines of Th17 cells are
IL-17 an IL-22. These cytokines support the epithelial barrier
integrity by stimulation of tight junction protein formation [13],
and IL-22 has an important role in epithelial cell survival and
proliferation [14]. Th17 cells also act as ﬁrst defense against mi-
crobes by stimulating the production of antimicrobial peptides and
chemokines to attract leukocytes when the epithelial barrier is
breached [15]. Initially, activation and polarization of Th17 cells
may be initiated by dendritic cells in lymph nodes draining the
salivary and lacrimal glands, whereas in later phases of the disease
this may also happen locally in the inﬂamed glandular tissue. These
dendritic cells secrete Th17 cell polarizing cytokines, including
TGF-b and IL-23 (Fig. 1). Ductal epithelial cells of the glands may
also produce cytokines important for Th17 polarization, such as IL-
1b [16]. Activated Th17 cells promote inﬂammation by stimulating
release of pro-inﬂammatory cytokines in the inﬂamed exocrine
glands, including IL-6 and TNF, by virtue of IL-17 and IL-22 secretion
and its binding to their receptors expressed on stromal and
epithelial cells [17] (Fig. 1). Expression of IL-17R was observed in a
neoplastic parotid gland cell line [10], and is likely also expressed
by ductal epithelial cells in pSS patients. IL-17 was also shown to
induce matrix metalloproteinase 1 (MMP-1) and MMP-3 release
from synovial ﬁbroblasts in rheumatoid arthritis, which may cause
tissue destruction [18]. In salivary gland tissue of pSS patients,
particularly MMP-9 expression is increased and is associated with
acinar damage [19]. Interleukin-17 also promotes MMP-9 produc-
tion by epithelial cells [20].
In addition to their role in tissue inﬂammation, Th17 cells also
may contribute more speciﬁcally to autoimmune processes by the
following mechanisms (i) supporting isotype class switching upon
B cell receptor stimulation, both via IL-17 and IL-21 production
[21,22], (ii) regulating glycosylation of autoreactive antibodies [23],
(iii) affecting trafﬁcking of B cells within the GC resulting in
disturbed selection of B cells and formation of autoantibodies [24]
and (iv) supporting formation of ectopic lymphoid tissue and
ectopic germinal centers (GCs) [24e26] (Fig. 1). Whether these
functions of Th17 cells are involved in pSS pathogenesis is currently
unknown. There is some support for a role of IL-22 in ectopic
lymphoid tissue formation in pSS. Administration of luciferase-
encoding replication-defective adenovirus (Ad5) through intra-
ductal cannulation into the salivary glands of C57BL/6 mice leads to
lymphocytic inﬁltration of these glands, and ectopic lymphoid
tissue formation. Knockout or blockade of IL-22 in this model
impaired ectopic lymphoid tissue formation [27]. This was probably
caused by reduced IL-22-mediated CXCL12 and CXCL13 production
by stromal cells in these IL-22 deﬁcient animals. In summary,
numerous potential effector functions of Th17 cells may contribute
to pathogenesis in autoimmune conditions in general, and pSS in
particular [28].
3. Th17 cells and glandular inﬂammation in pSS
Interleukin-17 protein andmRNA, as well as cells expressing the
Th17-associated transcription factor RORg, are present in minor
Table 1
Evidence for the involvement of Th17 cells in pSS pathogenesis.
Reference Publication Study population Key observations related to Th17 cells
Human
[8] Verstappen et al., 2017 pSS patients before and after
abatacept treatment
Patients with pSS have elevated frequencies of circulating Th17 cells (CCR6þCCR4þ),
compared with controls. These cells are not affected by abatacept treatment.
[9] Nguyen et al., 2008 pSS patients Protein expression of IL-17 and IL-23 in lymphocytic foci in minor salivary glands of pSS
patients. IL-17 levels in serum and saliva of pSS patients comparable to non-SS sicca
patients.
[10] Sakai et al., 2008 pSS patients Protein expression of IL-17 in minor salivary glands was predominantly found in CD4þ T
cell areas, but also co-localized to some extent with CD8þ T cells and ductal epithelial
cells.
[11] Katsiﬁs et al., 2009 pSS patients Local IL-17 protein and mRNA levels, together with IL-6 and IL-23 mRNA, increase with
progression of lesion severity in minor salivary glands of pSS patients. Plasma IL-17 levels
were signiﬁcantly higher in pSS patients, compared with controls.
[29] Ciccia et al., 2014 pSS patients before and after RTX
treatment
Salivary gland expression of IL-17, but not of IL-23p19 and p-STAT3, decreased by
rituximab treatment.
[30] Liu et al., 2017 pSS patients IL-17A conjunctival mRNA and protein expression in tears higher in pSS, compared with
non-SS group with dry eye disease.
[33] Ciccia et al., 2012 pSS patients IL-22 is present in minor salivary gland tissue of pSS patients and Th17 cells are a major
source of this cytokine.
[44] Blokland et al., 2017 pSS patients Percentages of peripheral IL-17-producing CD4þ T cells were similar between pSS
patients and controls. CCR9þ Th-cells produced IL-17 upon antigen and IL-7 stimulation.
[54] Verstappen et al., 2017 pSS patients before and after RTX
treatment
Frequency of IL-17-producing CD4þ T cells in PBMCs from pSS patients at baseline was
similar to controls, but these cells signiﬁcantly decreased by rituximab treatment,
together with serum levels of IL-17.
[55] Bikker et al., 2012 pSS patients Ex vivo and IL-7-induced IL-17A production is similar in pSS patients and controls
[56] Kwok et al., 2012 pSS patients Higher frequency of IL-17-producing CD4þ T cells in PBMCs from pSS patients, compared
with controls.
[57] Pollard et al., 2013 pSS patients Several Th17-related cytokines (IL-17, GM-CSF, IL-1b) were signiﬁcantly elevated in pSS
patients, compared with controls.
[58] Reksten et al., 2009 pSS patients Higher levels of Th17-associated cytokines in pSS patients with germinal center (GC)
formation in their salivary glands, compared with GC-negative patients.
[62] Alunno et al., 2013 pSS patients IL-17-producing CD4CD8 T cells are expanded in PBMCs from pSS patients, are also
present in minor salivary glands and are resistant to in vitro dexamethasone suppression.
[63] Fei et al., 2014 pSS patients Glandular IL-17 protein expression increased with progression of lesion severity.
CD4þIL-17 þ cells in peripheral blood of pSS patients and serum IL-17 were signiﬁcantly
increased, compared with controls.
Mouse
[9] Nguyen et al., 2008 C57BL/6.NOD-Aec1Aec2 mice IL-17A, IL-17R and IL-23 expression in salivary glands when inﬁltrates occur, Tbet is
increased in the pre-disease phase.
[68] Voigt et al., 2016 C57BL/6.NOD-Aec1Aec2 x IL-17 KO
mice
IL-17 deﬁcient C57BL/6.NOD-Aec1Aec2 mice are protected against disease development.
[69] Wanchoo et al., 2017 C57BL/6.NOD-Aec1Aec2 mice TCR repertoires of Th1 and Th17 cells in salivary gland inﬁltrates are restricted.
[71] Lin et al., 2015 C57BL/6J and IL-17 KO mice with
ESS
Th17 cells are increased in salivary gland peptide induced disease. IL-17 deﬁcient mice
are protected, and transfer of Th17 cells in IL-17 deﬁcient mice restores disease
phenotype.
[72] Iizuka et al., 2015 RORgt Tg mice and RAG KO mice RAG deﬁcient mice develop pSS phenotype upon transfer of RORgt overexpressing CD4þ
T cells, but not when these cells are IL-17 deﬁcient.
[74] Lee et al., 2012 C57BL/6.NOD-Aec1Aec2 with IL27
expression in salivary glands
IL-27 expression through rAAV2-IL27 vector injection, which induces Th1 and inhibits
Th17 cells is most effective after onset of glandular disease
[81] Contreraz-Ruiz et al., 2017 TSP1 KO mice with TSP1 peptide
treatment
Treatment of TSP1 KO mice with TSP1 derived peptide increases Treg cells and reduces
Th17 cells, and attenuates disease symptoms.
[82] Coursey et al., 2017 NOD.B10.H2b Treg cell function is hampered and Treg cells cells start to produce IL-17 and IFNg.
[90] Iizuka et al., 2010 M3R KO and RAG KO mice Transfer of M3R deﬁcient splenocytes in RAG deﬁcient mice leads to Th17.1 inﬁltration in
salivary glands and pSS like symptoms.
[91] Tahara et al., 2017 M3R KO and RAG KO mice with
anti-RORgt treatment
RORgt antagonist treatment after transfer of M3R deﬁcient splenocytes into RAG
deﬁcient mice reduces both IL-17 and IFNg in spleen and LN.
[98] Nguyen et al., 2010 C57BL/6J with IL-17A expression in
salivary glands
IL-17A expression through Adenovirus 5 cannulation in salivary glands leads to pSS-like
phenotype
G.M. Verstappen et al. / Journal of Autoimmunity 87 (2018) 16e2518salivary gland tissue of pSS patients, mainly in CD4þ T cell-rich
areas [9e11,29,30]. IL-17 is also present in saliva and tears from
pSS patients, and in tears, levels are higher compared with non-SS
sicca controls [30,31]. Although it is likely that Th17 cells are the
main source of IL-17 in the inﬂamed exocrine glands, gd T cells, NK
cells, innate lymphoid cells (ILCs) including lymphoid tissue
inducer cells, and CD8þ T cells are also potent sources of IL-17 [28].
Double negative (CD4CD8) T cells and CD8þ T cells that are
positive for IL-17 are actually present in minor salivary glands of
pSS patients, albeit in low numbers. Immunohistochemical analysis
initially suggested that also mast cells were a source of IL-17 in
inﬂamed salivary glands [29]. Recent ﬁndings show, however, that
mast cells do not produce IL-17 themselves, but actively capture IL-17 by endocytosis [32].
The number of IL-17-positive cells and IL-17 mRNA levels in
minor salivary gland biopsies correlate with focus score, a measure
of glandular inﬂammation [11]. Another Th17 cell-associated
cytokine that is present in salivary gland tissue of pSS patients is
IL-22, which seems to co-localize with mononuclear cells and
ductal epithelial cells [33]. The same study showed that, after
in vitro stimulation, IL-22 is mainly co-expressed by IFN-g- or IL-
17-producing CD4þ T cells isolated from minor salivary glands and
only a small proportion of CD4þ T cells expressed IL-22 alone [33].
The IL-22 receptor (IL-22R) is usually expressed by non-
hematopoietic cells at barrier surfaces [34]. However, only few
ductal and acinar epithelial cells in the salivary glands of pSS and
Fig. 1. Role of Th17 cells in pSS patients. 1) Environmental factors activate epithelial cells and dendritic cells (in blue). These cells secrete pro-inﬂammatory cytokines and present
antigens, resulting in activation of Th17 cells. 2) Th17 cells inﬁltrate the salivary gland and may differentiate towards Th17.1 cells or Th1 cells. Pro-inﬂammatory cytokines (IL-17A, IL-
22, IFNg) are secreted by these cells and bind to their receptors expressed on stromal and epithelial cells. Tissue inﬂammation is exacerbated and more pro-inﬂammatory factors are
secreted by epithelial cells. 3) CXCL12 and CXCL13 are expressed by stromal and epithelial cells and, together with antigen presentation by follicular dendritic cells, can induce
germinal center (GC) formation in salivary glands. 4) The GC generates plasma cells producing autoantibodies en memory B cells switched to IgG, which is stimulated by IL-17 and
IL-21. 5) B cells in secondary lymphoid organs and salivary glands produce IL-6, further stimulating formation of Th17 cells. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
G.M. Verstappen et al. / Journal of Autoimmunity 87 (2018) 16e25 19non-SS sicca patients seem to express IL-22R, and aberrant protein
expression of IL-22R was observed among inﬁltrating mononuclear
cells in pSS patients [35]. The nature and function of this IL-22R
expression on mononuclear cells is, however, unclear.
The developmental origin of IL-17- and IL-22-expressing T cells
in salivary glands is not exactly known, and both local differentia-
tion from naïve CD4þ T cells as well as recruitment of Th17(-like)
effector cells from the peripheral blood may contribute to the
local pool of IL-17- and IL-22-expressing cells (Table 2). Naïve Tcells
can differentiate locally into Th17 cells in the presence of antigen
presenting cells (APCs) and the essential cytokines IL-6 and TGF-b
[36]. IL-6 is present in salivary gland tissue and saliva of pSS pa-
tients and local IL-6 expression increases with a higher focus scoreTable 2
Ligands and receptors that promote Th17 cell polarization, recruitment and maintenance
Local polarization of naïve CD4þ T cells into Th17 phenotype
Expressed by naïve/activated T cell Ligand Expressed by
IL-6 receptor IL-6 APC, ductal epithelial cells
TGFb receptor TGFb APC
IL-21 receptor IL-21 Tfh cells/Th17 cells
CXCR3 CXCL9/CXCL10 ductal epithelial cells (among
Expressed by Th17 cell Ligand Expressed by Ef
Recruitment of Th17 cells to the salivary glands
CCR6 CCL20 salivary gland epithelial cells (low expression) ho
CCR7 CCL19/
CCL21
salivary gland stromal cells (high expression) ho
CCR9 CCL25 inﬂamed salivary gland tissue (epithelial cells) ho
Maintenance of Th17 cells in salivary glands
IL-23 receptor IL-23 APC ex
IL-7 receptor IL-7 salivary gland stromal cells m
IL-15 receptor IL-15 salivary gland epithelial cells m[37]. TGF-b is also produced in salivary gland tissue of both healthy
individuals and pSS patients [11]. Th17 cell differentiation is further
ampliﬁed by IL-21 and this cytokine is abundantly expressed in the
glandular inﬁltrate of pSS patients [38,39]. In addition to IL-6 and
TGF-b, also the pro-inﬂammatory chemokines CXCL9 and CXCL10
may play a role in local polarization of Th17 cells. Activated CD4þ T
cells may express CXCR3 and ligation of CXCR3 not only leads to
upregulation of Tbet, the transcription factor driving Th1 cell dif-
ferentiation, but also to RORg expression and Th17 cell formation
[40]. In this context it is relevant to mention that CXCL9 and in
particular CXCL10 are secreted in high quantities by ductal
epithelial cells from pSS patients in response to IFN-g [41] and
likely also to IFN-a [42].in (inﬂamed) human salivary glands.
Effect Reference
IL-6 and TGFb together promote Th17 differentiation by
upregulating RORgt and IL-23R expression on Th17 cells
[11,36,37]
ampliﬁcation of Th17 differentiation [38,39]
others) upregulation of Tbet and RORgt in T cells [40e42]
fect Reference
ming of Th17 cells to salivary glands and activation of these cells [43,47,45]
ming of naïve T cells and central memory Th17 cells to salivary glands [48,49]
ming of CCR9þIL-17 þ T cells to salivary glands [44]
pansion and maintenance of Th17 cells and production of cytokines [9,11,28]
aintenance of pathogenic Th17 cells [51,52]
aintenance of pathogenic Th17 cells [51,53]
G.M. Verstappen et al. / Journal of Autoimmunity 87 (2018) 16e2520Besides local differentiation of naïve cells and polarization of
Th1 cells, Th17 cells can also be recruited from the circulating pool
of Th17 cells by chemokines that are secreted in the salivary glands.
An important pathway for direct recruitment of Th17 cells to the
inﬂamed tissue is via the CCL20/CCR6 signaling axis [43,44]. CCL20
is not only important for recruitment of Th17 cells, but also for
activation of these cells, as binding of CCL20 to CCR6 induces cal-
cium inﬂux in Th17 cells [45]. CCL20-mRNA transcripts were,
however, only detected at low levels and in few pSS patients as
revealed by qPCR [46,47]. Thus, the role for CCL20 in the recruit-
ment of Th17 cells to the salivary glands seems limited. Th17(-like)
cells may, however, also be attracted by other chemokines, such as
CCL25/CCR9. Recently it was shown that IL-17-producing CCR9þ T
cells home in small numbers to the inﬂamed salivary gland under
the inﬂuence of CCL25 [44]. Another signaling axis that may
contribute to recruitment of both naïve and central memory (Th17)
cells consists of CCR7 and its ligands CCL19 and CCL21, all of which
are highly expressed in salivary gland tissue of pSS patients [48,49].
Not only pro-inﬂammatory cytokines that induce or amplify
Th17 cell differentiation, but also cytokines that are important for
homeostasis of Th17 cells may contribute to Th17-mediated pa-
thology in inﬂamed tissue. IL-23 is important for expansion and
maintenance of Th17 cells by STAT3 activation and is present in
glandular inﬁltrates [9,11,28]. Production of IL-23 by macrophages
is at least in part mediated by the activation of interferon regulatory
factor 5 (IRF5) [50]. Interestingly, polymorphisms of the IRF5 gene
locus are associated with pSS and may enhance IL-23 production
[2]. IL-7 and IL-15 can also sustain pathogenic Th17 cells, which is
mediated by STAT5/Akt signaling [51]. Elevated levels of IL-7 are
observed in minor salivary glands of pSS patients, compared with
non-SS sicca patients, and IL-7 is largely produced by stromal cells
in the glands [52]. IL-15 can be produced by salivary gland epithelial
cells of pSS patients in response to TLR2 stimulation in vitro [53].
Taken together, the inﬂamed exocrine glands in pSS constitute a
microenvironment that enables local polarization and recruitment
of (precursor) Th17 cells. Although their contribution to the disease
is not clear yet, local Th17 cells can acquire several effector func-
tions that are potentially pathogenic.
4. Th17 cells and systemic inﬂammation in pSS
In addition to glandular Th17 cell activity, also circulating
Th17 cells and serum levels of IL-17 have been studied in the past
decade in pSS, but with conﬂicting results [9,11,54e58]. Some
studies report an increase in circulating Th17 cells and/or serum
levels of IL-17, whereas others do not ﬁnd a difference between pSS
patients and healthy controls. It should be noted that different
deﬁnitions of Th17 cells were used in these studies.
Recently, we found in two independent study cohorts that
proportions of circulating Th17 cells, as deﬁned by their chemokine
receptor expression proﬁle (CD4þCD45RA-FoxP3-CXCR5-CXCR3-
CCR4þCCR6þ), were increased in pSS patients compared to
healthy controls [8,54]. Both studies included patients with mod-
erate systemic disease activity, as measured by ESSDAI, the EULAR
Sj€ogren's Syndrome Disease Activity Index (median ESSDAI scores
in these study cohorts: 11 and 8, respectively). Despite this increase
in chemokine-receptor deﬁned Th17 cells in these patients, pro-
portions of circulating CD4þIL-17 þ T cells were not elevated [54],
consistent with a previous report [55]. The relative increase in
Th17 cells, as deﬁned by chemokine receptor expression, was not
observed when comparing pSS patients with non-SS sicca patients
in a diagnostic cohort that included patients clinically suspected
with pSS (Verstappen & Kroese, unpublished data). In this cohort,
systemic disease activity in pSS patients was low (median ESSDAI
score ¼ 4). These ﬁndings indicate that elevated levels of Th17 cellsare possibly only seen in pSS patients with moderate to high sys-
temic disease activity.
Alternative deﬁnitions of Th17 cells have been adopted to study
the prevalence of Th17 cells in peripheral blood of pSS patients. For
example, expression of the C-type lectin CD161, in combination
with RORg, the master transcription factor required for generation
of Th17 cells and IL-17 production, has been used [59]. In pSS pa-
tients, CD4þCD161þRORgþ T cells were increased and this increase
correlated positively with anti-SSA/SSB autoantibody status and
serum IgG level, but not with systemic disease activity, as measured
by ESSDAI [60]. Recent ﬁndings show that, in addition to typical
CCR4þCCR6þ Th17 cells, also circulating ‘Tfh-like’ CCR9þCD4þ and
CXCR5þCD4þ T cells from pSS patients are capable of producing IL-
17 [44]. Regarding the latter Tfh-like subset, a fraction of these cells
appears to co-express CCR6, and thus may also be considered as a
Th17 cell subset. These CD4þCXCR5þCCR6þ T cells were elevated
in peripheral blood of pSS patients [61]. Lastly, circulating double
negative (CD4CD8) T cells, which consist largely of gdþ T cells,
are a potential source of IL-17 in pSS patients [62]. Also these
double negative T cells that produce IL-17 are expanded in pe-
ripheral blood of pSS patients [62]. The chemokine receptor proﬁle
of double negative T cells still needs to be deﬁned.
Even though deﬁnitions of Th17 cells vary, these cells thus seem
to be increased in peripheral blood of pSS patients. Likely, both
circulating and local Th17 cells contribute to serum levels of IL-17,
although, as mentioned before, also other cell types are able to
produce this pivotal Th17 cell cytokine. Nearly all studies showed
increased IL-17 (i.e. IL-17A) levels in serum of pSS patients. How-
ever, a correlation between serum IL-17 levels and disease activity
has not been reported [9,11,57,58,63,64]. Reksten et al. showed that
serum levels of IL-17 were higher in pSS patients with GCs in their
minor salivary gland biopsies compared to GC-negative patients
[58]. Subsequently they observed that serum IL-17 levels correlated
positively with levels of anti-Ro/SSA and anti-La/SSB autoanti-
bodies, but not with clinical features of the disease [64]. These
ﬁndings, together with our observations that circulating Th17 cells
are increased only in patient cohorts with moderate-to-high sys-
temic disease activity, but not in patients with low systemic disease
activity, indicate that numbers of circulating Th17 cell and levels of
serum IL-17 are associated with disease severity and/or with
certain stages of the disease. In line with this notion, a positive
correlation between disease duration and levels of circulating
Th17 cells and serum IL-17 was observed in mouse models of pSS
[65].
5. Th17 cells in mouse models of pSS
Mouse models of pSS are very useful to study aspects of the
disease that otherwise cannot be addressed. Although thesemodels
often only mimic part of the pathology found in pSS patients, they
do give important insights in the role of individual cells or cyto-
kines, and provide the opportunity to study disease kinetics.
The most extensively used animal model to study pSS is the
C57BL/6.NOD-Aec1Aec2 mouse. These mice harbor two suscepti-
bility loci that promote a spontaneous pSS-like autoimmune
phenotype, featuring salivary and lacrimal gland dysfunction
leading to decreased saliva production and ocular inﬂammation
[66]. In these mice, RORgt, IL-17 and IL-17R mRNA expression were
found in the salivary (submandibular) glands [9]. Elevated IL-17 and
IL-17R expression was also seen at the ocular surface [67]. Corre-
spondingly, Th17 cells were present in the immune inﬁltrates in
salivary and lacrimal glands of affected mice [67,68]. However, only
low levels of IL-17 were found in serum of these mice [9]. Despite
these low serum IL-17 levels, IL-17 seems to play an important role
in pSS-like disease in this model. This is illustrated by the
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signiﬁcantly reduces the pro-inﬂammatory response in the salivary
glands and restores normal secretory function, particularly in fe-
male animals [68]. In addition, these mice exhibit an altered
speciﬁcity of auto-antibodies compared to IL-17-sufﬁcient C57BL/
6.NOD-Aec1Aec2 mice, illustrating the role of IL-17 in promoting
autoreactive B cells responses. This effect is probably mediated by
affecting the numbers of both GC B cells and plasma cells [68].
These data suggest that IL-17 is particularly pathogenic at the site of
inﬂammation. This is further supported by a model in which SS-
non-susceptible C57BL/6J mice received local IL-17A gene transfer
in the salivary glands, resulting in glandular inﬂammation, auto-
antibody production and decreased saliva production [69]. In
addition to pro-inﬂammatory roles of IL-17 in C57BL/6.NOD-
Aec1Aec2 mice, a recent study also shows that T cell receptor rep-
ertoires of Th1 and Th17 cells in the salivary glands are limited
compared towild type controls, particularly in female animals [69],
suggesting they may be skewed towards recognition of
autoantigens.
In a second mouse model of pSS, disease is induced by immu-
nization with autoantigenic peptides derived from salivary glands
[70]. Also in these mice, Th17 cells are abundantly present in the
salivary gland inﬁltrates and draining lymph nodes, and are the
main IL-17 producing T cell subset [70]. In parallel, these mice have
high serum levels of IL-6 and TGFb, which are essential cytokines
for Th17 differentiation. Importantly, IL-17-deﬁcient mice immu-
nized with salivary gland peptides are completely protected from
disease development and adoptive transfer of Th17 cells (polarized
in culture) to these mice restores the autoimmune phenotype [71].
Also a third mouse model, in which RORyt is overexpressed, illus-
trates the importance of Th17 cells in development of pSS-like
disease [72]. These mice exhibit increased IL-17 production by T
cells and concomitantly pSS-like features including salivary and
lacrimal gland inﬂammation and autoantibody production [72].
Increased expression of CCR6 was found on splenic CD4þ T cells in
these mice, and the ligand for CCR6 (i.e. CCL20) was abundantly
expressed in the salivary glands, enabling homing of circulating
Th17 cells to these glands [72].
These models not only reveal that Th17 cells are crucial cells for
development of pSS-like disease, but also give important clues
about their relevance at different time points of disease onset and
progression. In the C57BL/6.NOD-Aec1Aec2 mice, IL-17, IL-23 and
RORgt expression increase when the inﬁltrates arise in the salivary
glands, whereas they drop again after development of full-blown
disease [9]. These ﬁndings suggest that Th17 cells may play a
local temporal role at early stages of the disease. However, before
the function of Th17 cells becomes apparent, Th1 cells appear to be
involved. Even before inﬁltrates are formed in the salivary glands,
levels of Tbet, the transcription factor driving Th1 cell differentia-
tion, are increased in submandibular glands, in line with the crucial
role for IFNg in the pre-clinical onset of disease in NODmice [9,73].
This temporal balance between Th1 and Th17 cells in the glandular
tissue may determine the development of the autoimmune
phenotype. This is further illustrated by gene therapy of these
C57BL/6.NOD-Aec1Aec2 mice with IL-27, a cytokine that promotes
Th1 and inhibits Th17 development. Initiation of treatment after
disease onset, i.e. at a time point when Th17 cells are thought to
play a role, is more effective than treatment before disease onset,
i.e. when Th1 cells are involved [74]. Also in the salivary gland
peptide-immunized model, ﬁrst Th1 cells are increased in the
salivary glands, and later on Th17 cells predominate [71].
Taken together, there is strong evidence in mice that Th17 cells
are a driving force in the pathogenesis of pSS(-like) disease. The pSS
mouse models further indicate that Th17 cells and IL-17, are
particularly involved in the early phase of disease, a ﬁnding thatmay be more challenging to conﬁrm in pre-clinical disease in
humans.
6. Th17/Treg imbalance in pSS
Autoimmune diseases are frequently linked to an altered Th17/
Treg ratio and commitment to one of these lineages is tightly
regulated by distinct signaling molecules [75]. Available evidence
indicates that there is, however, no imbalance in proportions of
effector Th17 cells and Treg cells in pSS patients, as both subsets are
equally increased in the periphery of pSS patients with moderate
systemic disease activity [8]. Furthermore, the numbers of both
Th17 cells and FoxP3þ cells in minor salivary gland tissue correlate
positively with focus score/grade of inﬂammation [11,76]. It is not
known though whether the population of FoxP3þCD4þ T cells in
pSS patients is functionally normal and is able to suppress effector T
cells.
Although these observations strongly argue that there is no
Th17/Treg imbalance in human pSS, several mouse models suggest
that an imbalance between Th17 cells and Treg cells could underlie
the development of this disease (Fig. 2). This imbalance may be a
result of increased IL-6 in the inﬂammatory environment. TGFb in
the absence of IL-6 induces Treg differentiation, but TGFb and IL-6
together promote Th17 differentiation [77]. In C57BL/6.NOD.Ae-
c1Aec2 mice, Treg cells are decreased compared to wild-type con-
trol mice in the lacrimal gland already at an early pre-clinical
disease age, when Th17 cell numbers and IL-17A expression are
increased [67]. Consistent with these ﬁndings, transient depletion
of Treg cells in NOD mice led to increased salivary gland inﬁltrates
[78]. A role for Th17/Treg imbalance in disease induction is further
illustrated in mice lacking thrombospondin-1 (TSP1), an important
activator of latent TGFb in vivo [79]. These mice spontaneously
develop ocular inﬂammation accompanied by dry eye symptoms
and anti-SSA and anti-SSB antibodies [80]. Increased splenic
Th17 cells and lacrimal IL-17 protein levels in these mice were
accompanied by a decrease in splenic Treg cells [80]. In vivo
administration of TSP1-peptide to TSP1 knock-out mice induced
formation of FoxP3þ Treg cells, and decreased Th17 cells, attenu-
ating symptoms of disease [81].
In a different NOD model bearing an altered MHC region
(NOD.B10.H2bmice), animals spontaneously develop ocular surface
disease upon aging. In these aged mice, FoxP3þ Treg cells aber-
rantly co-express Tbet and RORgt and produce IFN-g and IL-17. At
the same time, aged Treg cells in NOD.B10.H2b mice exhibit lower
suppressive capacity compared to Treg cells from young mice.
Transfer of CD4þCD25þ Treg cells from these agedmice into T and B
cell-deﬁcient (RAG1-deﬁcient) animals induced a similar pheno-
type of periductal inﬂammation in the lacrimal glands as transfer of
CD4þCD25 T helper cells [82]. These results conﬁrm that Treg cells
can acquire pro-inﬂammatory features associated with Th1 and
Th17 cells.
Together, these murine models illustrate that not only the
enhanced pro-inﬂammatory features of Th17 cells can promote
disease, but that changes in Treg cells, both in number or function,
may contribute to disease progression. Functional assays with hu-
man Treg cells from pSS patients could clarify whether decreased
suppressive capacity or even pro-inﬂammatory capacity of Treg
cells also plays a role in the development of disease in patients.
7. Plasticity of Th17 cells in pSS
Both in humans andmice, Th17 cells are not a “ﬁxed” subset, but
can acquire features from, or differentiate towards, other effector
types, i.e. Th1 and Treg cells [83]. The transformation of typical
Th17 cells towards Th17.1 cells is most intensively studied,
Fig. 2. Insights on Th17 cell plasticity from pSS mouse models. In a healthy situation, there is no inﬂammation in the salivary glands and at the ocular surface. Treg cells control Th1
cells, Th17 cells and the small number of Th17.1 cells present in the body. However, in mice with pSS-like disease, IL-6 levels increase, shifting the balance between Treg cells and
Th17 cells. Treg cells are reduced in number, lose their regulatory capacity and sometimes start producing IL-17 and IFNɣ. Simultaneously, the number of Th17 cells increases, and
these cells can convert to IL-17 and IFNɣ producing Th17.1 cells, or to IFNɣ single producing Th1-like cells. Together, these cells can promote germinal center formation, and support
differentiation of B cells into class-switched plasma and memory cells.
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Th17.1 cells co-express CXCR3 and CCR6 and produce both IL-17 and
IFN-g.
Plasticity of Th17 cells in humans is, however, a relatively un-
explored ﬁeld. In patients with Crohn's disease, Th17.1 cells are
pathogenic and promote chronic inﬂammation [85]. Furthermore,
in patients with multiple sclerosis Th17.1 cells reacted strongly
against self-antigens [86]. The factors that drive this plasticity in
humans are not fully understood, but some indications may come
from a murine model of experimental autoimmune encephalo-
myelitis. In these mice, transformation of Th17 cells to both IFN-g-
single producing Th1 cells and IFNg/IL-17 double producing
Th17.1 cells was driven by high IL-7 expression [87]. Interestingly, in
salivary gland tissue of pSS patients, IL-7 is abundantly present [52],
and may drive the plasticity of Th17 cells to IFN-g single or double
producing Th17.1 cells. Besides plasticity of Th17 cells, plasticity of
other effector T cell subsets may also contribute to the pathology
seen in pSS patients. For example, it has been shown in mice with
experimental autoimmune encephalomyelitis (EAE) that Tfh cells
can aberrantly express IL-17, and these IL-17-producing Tfh cells
could augment the formation of autoreactive B cells by stimulating
ectopic germinal center formation and impairing chemotactic
migration of B cells out of the germinal center [26]. Aberrant
expression of IL-17 by Tfh cells may also play a role in later phases of
pSS pathogenesis when germinal center containing ectopiclymphoid tissue is present.
The possible contribution of Th17 cell plasticity to pathogenicity
in pSS is further illustrated by a Sj€ogren mouse model driven by an
immune response against the M3 muscarinic acetylcholine recep-
tor (M3R) [88]. Under physiological conditions, cholinergic stimu-
lation of these receptors leads to an increase of saliva secretion.
Immunization of M3R-deﬁcient mice with M3R peptides induces a
strong immune response that results in formation of autoanti-
bodies directed against M3R, that block the cholinergic stimulation
and lead to reduced saliva production. Such blocking autoanti-
bodies against these receptors have also been described in human
pSS patients [88,89]. Besides autoantibody formation, the M3R
immunized mice exhibit an increase in IL-17A and IFNg producing
Th17.1 cells in the spleen [90]. Adoptive transfer of splenocytes
from these mice into T- and B-lymphocyte deﬁcient animals
induced severe pSS-like disease with anti-M3R autoantibody for-
mation and Th17.1 cells inﬁltrating the salivary glands associated
with decreased saliva production [90]. Treatment of these mice
with a RORgt antagonist after the transfer of splenocytes, reduced
both IL-17 and IFNg in vivo, and partially abrogated disease [91].
These data suggest that Th17 cells could co-produce IL-17 and IFNg,
or that Th17 cells might convert to Th1 cells post-transfer. Although
this model is not completely equivalent to pSS pathogenesis, it does
show many similarities with human disease, including inﬂamma-
tion speciﬁcally of the salivary and lacrimal glands, but not of the
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nuclear inﬁltrates in the glands.
In summary, although the data are scarce, they indicate that
plasticity of Th17 cells towards more pathogenic Th17.1 cells or Th1
cells may contribute to disease progression in pSS.
8. Effect of treatment on Th17 cells/IL-17 in pSS
Immunomodulatory treatment of pSS patients may provide
important insights into the role of various cell types in pathogen-
esis. One of the ﬁrst biological DMARDs that was clinically tested in
pSS patients was the TNF-alpha inhibitor etanercept. Markers of
activation on B cells and CD4þ T cells were not signiﬁcantly altered
by etanercept treatment, in line with a lack of clinical beneﬁt [92].
Plasma IL-17 levels were also unaffected [11]. Subsequently, several
studies assessed the efﬁcacy of B cell depletion therapy with rit-
uximab. Although the clinical beneﬁts are a matter of debate [93],
many biological parameters are affected, including Th17 cell-
related biomarkers [94]. Rituximab treatment resulted in
decreased IL-17 protein expression in minor salivary gland tissue of
pSS patients, despite the ﬁnding that factors that are important for
maintenance of Th17 cell, viz. pSTAT3 and IL-23, were not altered
[29]. Dendritic cells and macrophages are major sources of IL-23
and these cells are likely not affected by B cell depletion therapy
[39]. In addition to reduced IL-17 expression in the salivary glands,
we found decreased frequencies of circulating IL-17 þ CD4þ T cells
and to a smaller extent also chemokine receptor-deﬁned Th17 cells
after rituximab treatment [54]. The decrease of IL-17 þ CD4þT cells
over time correlated with decreasing levels of IgG and autoanti-
bodies, suggesting that IL-17 and autoantibody formation are
somehow related. Also serum levels of IL-17 decreased in this study
[54]. In a previous study, we found that serum IL-6 levels were also
signiﬁcantly reduced by rituximab treatment [57]. We therefore
postulated that the effect of B cell depletion therapy on Th17 cells
and IL-17 production is mediated by depletion of IL-6-producing B
cells [54]. As mentioned before, IL-6 supports Th17 cell differenti-
ation from naïve T cells and is important for the induction of RORg
and IL-17 [95]. In summary, rituximab affects Th17 cells locally and
systemically, although the mechanism of this effect and its contri-
bution to amelioration of disease remains to be established.
As T cell activation and crosstalk between B cells and CD4þ T
cells are important features in pSS pathogenesis, T-cell co-
stimulation appears to be a suitable target for treatment. Abata-
cept, which limits CD28-mediated co-stimulation and thereby
activation of T cells, was able to reduce systemic disease activity
(ESSDAI scores) in pSS patients in a small open-label study [96].
Although the fraction of circulating Tfh cells was signiﬁcantly
reduced by treatment, circulating Th17 cells (CD4þCD45RA-FoxP3-
CXCR5-CXCR3-CCR4þCCR6þ) were not affected. Also serum levels
of IL-17 did not change at a group level, but two patients with the
highest baseline levels did show a reduction in serum IL-17 [8].
Apparently, the clinical efﬁcacy of abatacept is not the result of a
signiﬁcant effect on the Th17/IL-17 axis. It is not knownyet whether
IL-17-producing cells in glandular tissue of pSS patients are affected
by abatacept treatment.
So far IL-17-targeting therapies have not been tested in pSS
patients. A case report from a patient with psoriasis and pSS treated
with ustekinumab, a monoclonal antibody directed against the p40
protein subunit shared by IL-12 and IL-23, showed beneﬁcial effects
not only on cutaneous disease, but also on joint involvement [97].
Effects on other pSS-related symptoms, such as dryness, were not
reported. A placebo-controlled trial with the IL-6R antagonist
tocilizumab is currently ongoing in pSS (NCT01782235). As naïve
CD4þ T cells express IL-6R and IL-6 signaling is important for Th17
differentiation, an effect of tocilizumab on Th17 cells is expectedand these results may provide more insight into the contributions
of Th17 cells to disease activity.
9. Conclusion
Both human and mouse studies clearly indicate that Th17 cells/
IL-17 producing T cells are involved in local inﬂammation in pSS
and SS-like disease. Their contribution to systemic disease is more
enigmatic. Th17 cells are elevated in the periphery of a subgroup of
pSS patients and higher systemic Th17 cell activity (serum IL-17
level, CD161þRORgþCD4þ cell frequency) correlates with
increased autoantibody titers. However, it remains to be estab-
lished if Th17 cells contribute directly to pathogenesis of human
pSS. A pathogenic role for Th17 cells is more evident in mouse
models of SS, where Th17 cells appear to play a key role in devel-
opment of the autoimmune phenotype. Pathogenicity of Th17 cells
in pSS is possibly linked to plasticity of this cell subset. In particular
plasticity towards Th17.1 cells, co-expressing IL-17 and IFN-g (and
CCR6 and CXCR3) may support chronic inﬂammation and B cell
activation in pSS patients (Figs. 1 and 2). Furthermore, mouse
models indicate that the major contribution of Th17 cells to disease
pathology may be temporal, early and locally in affected tissues.
Future studies are needed to clarify Th17 cell phenotypes in glan-
dular inﬁltrates and to address their contribution to disease onset
and progression.
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